Sarepta Therapeutics Inc

SRPT

Equity

ISIN US8036071004 / Valor 19028527

NASDAQ (2024-12-24)

USD 121.90+1.03%

Sarepta Therapeutics Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Sarepta Therapeutics Inc. is a global biotechnology firm focused on developing precision genetic medicines for rare diseases. The company leverages cutting-edge science in gene therapy, RNA technologies, and gene editing to address conditions that have limited treatment options. Sarepta's approach is characterized by its urgency to develop therapies that can significantly alter the course of diseases by targeting their genetic roots. With a portfolio that spans several advanced platforms, the company aims to provide transformative treatments in areas of high unmet medical need. Sarepta's commitment to innovation in genetic medicine positions it as a key player in the biotech industry, striving to offer hope and tangible solutions to patients facing life-altering diagnoses.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Sarepta Therapeutics Inc. reported a significant increase in total revenues for the third quarter of 2024, reaching $467.2 million. This marks a 41% growth compared to the same quarter in 2023, primarily driven by the successful launch and expanded label of ELEVIDYS.

Net Income

For the third quarter of 2024, Sarepta Therapeutics Inc. achieved a GAAP net income of $33.6 million, a notable improvement from a net loss of $40.9 million in the same period of the previous year. On a non-GAAP basis, the net income was $67.0 million, reflecting a 113% increase year-over-year.

Product Performance

ELEVIDYS, a key product for Sarepta Therapeutics Inc., generated net product revenue of $181.0 million in the third quarter of 2024. Including royalty revenue from Roche's sales, the total performance of ELEVIDYS reached $190.5 million for the quarter.

Operating Income

Sarepta Therapeutics Inc. reported a GAAP operating income of $22.2 million for the third quarter of 2024, compared to a loss of $20.8 million in the same quarter of 2023. On a non-GAAP basis, the operating income was $74.9 million, nearly doubling from the previous year.

Research and Development

Research and development expenses for Sarepta Therapeutics Inc. increased by $30.2 million in the third quarter of 2024 compared to the same period in 2023. This increase reflects the company's ongoing investment in its pipeline and portfolio prioritization efforts.

Summarized from source with an LLMView Source

Key figures

28.9%1Y

33.1%3Y

-9.23%5Y

Performance

48.4%1Y

56.5%3Y

62.5%5Y

Volatility